|1.||Levin, J: 4 articles (04/2002 - 04/2000)|
|2.||Hohneker, J: 4 articles (04/2002 - 04/2000)|
|3.||Spector, T: 4 articles (11/2000 - 02/2000)|
|4.||Rivera, Edgardo: 3 articles (02/2014 - 02/2002)|
|5.||Schilsky, R L: 3 articles (04/2001 - 04/2000)|
|6.||Spector, Thomas: 2 articles (02/2014 - 01/2010)|
|7.||Lockhart, Albert C: 2 articles (02/2006 - 03/2004)|
|8.||Petros, William P: 2 articles (02/2006 - 03/2004)|
|9.||Czito, Brian G: 2 articles (02/2006 - 03/2004)|
|10.||Tyler, Douglas S: 2 articles (02/2006 - 03/2004)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2003 - "The purpose of this study was to initially document inactivation of DPD by eniluracil in primary and metastatic colorectal cancer (CRC) and then to assess the time-course of the regeneration of DPD activity in peripheral blood (and where possible, additional tissues). "
11/01/2000 - "Administration of eniluracil 10 to 20 mg twice daily completely inactivates DPD activity both in peripheral blood mononuclear cells and in colorectal tumor tissue, and prolonged inhibition of DPD after discontinuation of eniluracil treatment has been noted. "
10/01/2000 - "Anesthetized rats bearing a subcutaneous rat colorectal tumor were given eniluracil or placebo and injected intravenously 1 h later with [18F]FU or [3H]FU. "
08/01/1999 - "Patients who were to undergo primary colorectal tumor resection received oral eniluracil 10 mg/m(2) twice daily for 3 days before surgery. "
08/01/2000 - "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer. "
11/01/2000 - "Eniluracil/5-FU has demonstrated efficacy as monotherapy in patients with a variety of solid tumors when given on a 5 or 28-day dosing schedule. "
10/01/2000 - "Eniluracil improved tumor visualization in PET images. "
08/01/1999 - "This study provides definitive evidence that eniluracil completely inactivates DPD activity in human solid tumors. "
01/01/2010 - "The rate of complete tumor regression (cure) was 0% in group A (no treatment), 88% in group B (adequate eniluracil), and 25% in group C (excess eniluracil). "
02/01/2006 - "Patients with resectable or locally advanced pancreatic and biliary cancer received eniluracil (starting at 6.0 mg/m(2) q12h)/5-FU (starting at 0.6 mg/m(2) q12h). "
|3.||Breast Neoplasms (Breast Cancer)
10/01/1998 - "Several phase II trials of 5-FU/eniluracil in breast cancer are ongoing. "
09/01/2001 - "The current study was done to determine the objective tumour response of a 28-day oral regimen of eniluracil-fluorouracil in patients with advanced breast cancer. "
09/01/2001 - "Treatment with oral eniluracil-fluorouracil was well tolerated by patients with advanced breast cancer. "
06/01/2000 - "Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study."
06/01/2000 - "First-line treatment with the combination of oral 5-FU and eniluracil has high activity in patients with advanced breast cancer comparable with the most active conventional cytotoxic agents but with strikingly less toxicity."
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|5.||Genetic Predisposition to Disease (Genetic Predisposition)
01/01/1997 - "Based on allometric analysis, the estimated clearance of 5-FU (10.9 l/h) in humans with DPD deficiency was comparable to the observed values in humans lacking DPD activity due to genetic predisposition (10.1 l/h), or treatment with 776C85 (7.0 l/h) or (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd, 6.6 l/h). "
|3.||Leucovorin (Folinic Acid)
|6.||2',3'- O- diacetyl- 5'- deoxy- 5- vinylcytidine
|9.||Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
|2.||Drug Therapy (Chemotherapy)